KÄÄPÄ Biotech Ltd

KÄÄPÄ Biotech Ltd is a Finland-based company specializing in the research and development of functional mushroom products that promote human health and ecological sustainability. KÄÄPÄ Biotech Ltd focuses on creating innovative mushroom-based health solutions. Founded in 2018 in Finland, the company has recently raised EUR 900,000 in funding from PeakBridge as part of their latest round in April 2025, bringing the total amount raised to EUR 900,000. The company has engaged in one notable deal.

KÄÄPÄ Biotech specializes in the research, innovation, and development of functional mushroom products aimed at enhancing human health and ecological sustainability. Their primary offerings include a range of mushroom-based ingredients and supplements designed to support wellness, leveraging the unique properties of fungi to address various health needs such as immune support, cognitive function, and overall vitality. These products cater to a diverse client base, including health-conscious consumers, dietary supplement manufacturers, and wellness-oriented retailers. KÄÄPÄ Biotech's products are strategically marketed in multiple geographical regions, including key markets in Europe and North America, ensuring a wide-reaching impact in the global health and wellness sector.

KÄÄPÄ Biotech utilizes a multi-faceted revenue model that encompasses direct-to-consumer sales, partnerships with health food retailers, and collaborations with businesses in the nutraceutical sector. The company engages in transactions through both wholesale distribution and online sales channels, providing clients with access to its range of functional mushroom products. The company’s revenue is generated from product sales, which may include flagship offerings that align with the growing demand for natural health solutions. By establishing partnerships and distribution agreements, KÄÄPÄ Biotech effectively enhances its market presence while catering to the evolving needs of health-oriented consumers and businesses.

In April 2025, KÄÄPÄ Biotech Ltd. raised EUR 900,000 in venture funding from PeakBridge. This funding will be utilized to scale the business to meet customer demand and enhance the visibility of functional mushroom ingredients in the global wellness market. The company is focused on developing new mushroom-based products and plans to expand into additional markets across Europe and North America by 2026.

In November 2025, KÄÄPÄ Biotech Ltd raised EUR 9 million in venture funding co-led by new investor Zintinus and returning investor PeakBridge. The company will use the November 2025 funding to support its growth and increase production capacity.